​

Blueprint Medicines (BPMC) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Blueprint Medicines Revenue Highlights

Latest Revenue (Y)

$508.82M

Latest Revenue (Q)

$149.41M

Main Segment (Y)

Collaboration and License

Main Geography (Y)

UNITED STATES

Blueprint Medicines Revenue by Period

Blueprint Medicines Revenue by Year

DateRevenueChange
2024-12-31$508.82M104.04%
2023-12-31$249.38M22.22%
2022-12-31$204.04M13.30%
2021-12-31$180.08M-77.31%
2020-12-31$793.74M1093.37%
2019-12-31$66.51M49.39%
2018-12-31$44.52M107.79%
2017-12-31$21.43M-22.85%
2016-12-31$27.77M143.61%
2015-12-31$11.40M100.00%
2014-12-31-100.00%
2013-12-31--

Blueprint Medicines generated $508.82M in revenue during NA 2024, up 104.04% compared to the previous quarter, and up 765.01% compared to the same period a year ago.

Blueprint Medicines Revenue by Quarter

DateRevenueChange
2025-03-31$149.41M2.08%
2024-12-31$146.37M14.18%
2024-09-30$128.18M-7.22%
2024-06-30$138.16M43.74%
2024-03-31$96.12M33.57%
2023-12-31$71.96M27.21%
2023-09-30$56.57M-1.74%
2023-06-30$57.57M-9.03%
2023-03-31$63.29M63.19%
2022-12-31$38.78M-41.22%
2022-09-30$65.98M80.53%
2022-06-30$36.55M-41.74%
2022-03-31$62.73M-41.38%
2021-12-31$107.02M342.46%
2021-09-30$24.19M-11.38%
2021-06-30$27.30M26.51%
2021-03-31$21.58M-36.74%
2020-12-31$34.11M-95.42%
2020-09-30$745.12M8831.06%
2020-06-30$8.34M35.28%
2020-03-31$6.17M-88.03%
2019-12-31$51.53M463.88%
2019-09-30$9.14M78.85%
2019-06-30$5.11M600.00%
2019-03-31$730.00K-29.33%
2018-12-31$1.03M-5.66%
2018-09-30$1.09M-97.36%
2018-06-30$41.44M4243.71%
2018-03-31$954.00K-41.40%
2017-12-31$1.63M-79.82%
2017-09-30$8.07M36.98%
2017-06-30$5.89M0.86%
2017-03-31$5.84M-24.07%
2016-12-31$7.69M24.85%
2016-09-30$6.16M-12.81%
2016-06-30$7.07M3.05%
2016-03-31$6.86M47.92%
2015-12-31$4.63M35.29%
2015-09-30$3.43M27.50%
2015-06-30$2.69M312.12%
2015-03-31$652.00K100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31--

Blueprint Medicines generated $149.41M in revenue during Q1 2025, up 2.08% compared to the previous quarter, and up 207.64% compared to the same period a year ago.

Blueprint Medicines Revenue Breakdown

Blueprint Medicines Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Collaboration revenue$3.30M----
Collaboration and License$24.30M----
Royalty$180.00K----
AYVAKIT and AYVAKYT-$204.21M$52.98M--
Product-$204.21M$110.99M$22.13M-
Product revenue, net---$57.69M-
GAVRETO---$4.71M-
Collaboration----$771.60M

Blueprint Medicines's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration and License (87.46%), Collaboration revenue (11.89%), and Royalty (0.65%).

Quarterly Revenue by Product

Product/ServiceMar 25Dec 24Sep 24Jun 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
Product$149.41M$128.18M$114.11M$125.26M$39.88M$39.07M$30.06M$8.96M$6.69M$6.31M$5.68M$3.46M--------
Collaboration and License--$27.63M$24.04M$3.59M---------------
Collaboration revenue-$1.37M$1.94M$15.86M----------------
Royalty--$198.00K-----------------
AYVAKIT and AYVAKYT-----$134.97M$34.31M$34.93M$30.06M$28.63M$28.45M$23.84M$20.03M$17.27M------
GAVRETO------$5.57M$4.14M-$4.71M----------
Product revenue, net---------$28.63M$28.45M$23.84M$20.03M$17.27M$11.43M-----
Collaboration---------------$12.62M$27.42M$738.81M$2.66M$2.71M

Blueprint Medicines's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Product (100.00%).

Blueprint Medicines Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24Dec 23Dec 22
Non-US$57.11M$22.24M$13.77M
UNITED STATES$421.84M$181.97M$97.23M

Blueprint Medicines's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (88.08%), and Non-US (11.92%).

Quarterly Revenue by Country

CountryMar 25Dec 24Sep 24Jun 24Mar 24
Non-US$19.97M$20.02M$15.05M$12.65M$9.39M
UNITED STATES$129.45M$124.11M$113.13M$101.46M$83.14M

Blueprint Medicines's latest quarterly revenue breakdown by geography, as of Mar 25: UNITED STATES (86.64%), and Non-US (13.36%).

Blueprint Medicines Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BPMCBlueprint Medicines$508.82M$149.41M
ROIVRoivant Sciences$124.80M$7.57M

BPMC Revenue FAQ

What is Blueprint Medicines’s yearly revenue?

Blueprint Medicines's yearly revenue for 2024 was $508.82M, representing an increase of 104.04% compared to 2023. The company's yearly revenue for 2023 was $249.38M, representing an increase of 22.22% compared to 2022. BPMC's yearly revenue for 2022 was $204.04M, representing an increase of 13.30% compared to 2021.

What is Blueprint Medicines’s quarterly revenue?

Blueprint Medicines's quarterly revenue for Q1 2025 was $149.41M, a 2.08% increase from the previous quarter (Q4 2024), and a 55.45% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $146.37M, a 14.18% increase from the previous quarter (Q3 2024), and a 103.41% increase year-over-year (Q4 2023). BPMC's quarterly revenue for Q3 2024 was $128.18M, a -7.22% decrease from the previous quarter (Q2 2024), and a 126.61% increase year-over-year (Q3 2023).

What is Blueprint Medicines’s revenue growth rate?

Blueprint Medicines's revenue growth rate for the last 3 years (2022-2024) was 149.38%, and for the last 5 years (2020-2024) was -35.89%.

What are Blueprint Medicines’s revenue streams?

Blueprint Medicines's revenue streams in c 24 are Collaboration revenue, Collaboration and License, and Royalty. Collaboration revenue generated $3.3M in revenue, accounting 11.89% of the company's total revenue Collaboration and License generated $24.3M in revenue, accounting 87.46% of the company's total revenue Royalty generated $180K in revenue, accounting 0.65% of the company's total revenue

What is Blueprint Medicines’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Blueprint Medicines was Collaboration and License. This segment made a revenue of $24.3M, representing 87.46% of the company's total revenue.